Finally, we show that amlexanox, an FDA‐approved drug targeting IKKε and its homologue TBK1, delays tumour appearance in vivo in a combined genetic mouse model of breast cancer and diet‐induced obesity. This evidence concerns the gene TBK1 and obesity due to melanocortin 4 receptor deficiency.